{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:17:27Z","timestamp":1791940647550,"version":"4.3.4"},"reference-count":112,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2020,8,4]]},"DOI":"10.1001\/jama.2020.10262","type":"journal-article","created":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T11:02:24Z","timestamp":1596538944000},"page":"488","source":"Crossref","is-referenced-by-count":746,"title":["Heart Failure With Reduced Ejection Fraction"],"prefix":"10.1001","volume":"324","author":[{"given":"Sean P.","family":"Murphy","sequence":"first","affiliation":[{"name":"Department of Medicine, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasrien E.","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Boston"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"James L.","family":"Januzzi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Boston"},{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Baim Institute for Clinical Research, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"7","key":"jrv200007r1","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/eurjhf\/hft050","article-title":"EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot).","volume":"15","author":"Maggioni","year":"2013","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"jrv200007r2","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"issue":"20","key":"jrv200007r3","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","article-title":"Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes.","volume":"70","author":"Shah","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"jrv200007r4","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","article-title":"Heart disease and stroke statistics-2020 update: a report from the American Heart Association.","volume":"141","author":"Virani","year":"2020","journal-title":"Circulation"},{"issue":"4","key":"jrv200007r5","first-page":"e29","article-title":"Heart disease and stroke statistics\u20142015 update: a report from the American Heart Association.","volume":"131","author":"Mozaffarian","year":"2015","journal-title":"Circulation"},{"issue":"10120","key":"jrv200007r6","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(17)32520-5","article-title":"Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals.","volume":"391","author":"Conrad","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"jrv200007r7","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1161\/CIRCHEARTFAILURE.112.972828","article-title":"Predictors of new-onset heart failure: differences in preserved versus reduced ejection fraction.","volume":"6","author":"Ho","year":"2013","journal-title":"Circ Heart Fail"},{"issue":"1","key":"jrv200007r8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jchf.2013.07.009","article-title":"Characterization of a novel symptom of advanced heart failure: bendopnea.","volume":"2","author":"Thibodeau","year":"2014","journal-title":"JACC Heart Fail"},{"issue":"6","key":"jrv200007r9","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jama.1989.03420060100040","article-title":"The limited reliability of physical signs for estimating hemodynamics in chronic heart failure.","volume":"261","author":"Stevenson","year":"1989","journal-title":"JAMA"},{"issue":"11","key":"jrv200007r10","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.jacc.2018.01.021","article-title":"N-terminal pro-B-type natriuretic peptide in the emergency department: the ICON-RELOADED study.","volume":"71","author":"Januzzi","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"jrv200007r11","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1056\/NEJMoa020233","article-title":"Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure.","volume":"347","author":"Maisel","year":"2002","journal-title":"N Engl J Med"},{"issue":"27","key":"jrv200007r12","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC.","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"issue":"5","key":"jrv200007r13","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.cardfail.2005.04.006","article-title":"NT-ProBNP reduction percentage during admission for acutely decompensated heart failure predicts long-term cardiovascular mortality.","volume":"11","author":"Bay\u00e9s-Gen\u00eds","year":"2005","journal-title":"J Card Fail"},{"issue":"9","key":"jrv200007r14","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.jacc.2019.06.055","article-title":"Natriuretic peptide response and outcomes in chronic heart failure with reduced ejection fraction.","volume":"74","author":"Januzzi","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"jrv200007r15","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1161\/CIRCULATIONAHA.119.039920","article-title":"Prognostic implications of congestion on physical examination among contemporary patients with heart failure and reduced ejection fraction: PARADIGM-HF.","volume":"140","author":"Selvaraj","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"jrv200007r16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.annemergmed.2005.04.003","article-title":"Prevalence of negative chest radiography results in the emergency department patient with decompensated heart failure.","volume":"47","author":"Collins","year":"2006","journal-title":"Ann Emerg Med"},{"issue":"5","key":"jrv200007r17","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1136\/hrt.2005.074583","article-title":"Use of chest radiography in the emergency diagnosis of acute congestive heart failure.","volume":"92","author":"Mueller-Lenke","year":"2006","journal-title":"Heart"},{"issue":"9","key":"jrv200007r18","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/0002-9149(89)90912-0","article-title":"Radiographic pulmonary congestion in end-stage congestive heart failure.","volume":"63","author":"Mahdyoon","year":"1989","journal-title":"Am J Cardiol"},{"issue":"10166","key":"jrv200007r19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(18)32484-X","article-title":"Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial.","volume":"393","author":"Halliday","year":"2019","journal-title":"Lancet"},{"issue":"16","key":"jrv200007r20","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1161\/CIR.0b013e31829e8807","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines.","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"issue":"2","key":"jrv200007r21","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jacc.2017.11.025","article-title":"2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.","volume":"71","author":"Yancy","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"jrv200007r22","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.cardfail.2011.04.011","article-title":"Impact of medication nonadherence on hospitalizations and mortality in heart failure.","volume":"17","author":"Fitzgerald","year":"2011","journal-title":"J Card Fail"},{"issue":"21","key":"jrv200007r23","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction.","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"20","key":"jrv200007r24","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction.","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"jrv200007r25","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry.","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"jrv200007r26","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jacc.2012.03.023","article-title":"Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial.","volume":"60","author":"Fiuzat","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"jrv200007r27","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1161\/01.CIR.94.11.2807","article-title":"Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure.","volume":"94","author":"Bristow","year":"1996","journal-title":"Circulation"},{"issue":"23","key":"jrv200007r28","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","article-title":"Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure.","volume":"100","author":"Packer","year":"1999","journal-title":"Circulation"},{"issue":"9704","key":"jrv200007r29","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","article-title":"Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial.","volume":"374","author":"Konstam","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"jrv200007r30","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/nrcardio.2016.163","article-title":"Neurohormonal activation in heart failure with reduced ejection fraction.","volume":"14","author":"Hartupee","year":"2017","journal-title":"Nat Rev Cardiol"},{"issue":"9146","key":"jrv200007r31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.","volume":"353","year":"1999","journal-title":"Lancet"},{"issue":"10","key":"jrv200007r32","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1001\/jama.283.10.1295","article-title":"Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR\/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF).","volume":"283","author":"Hjalmarson","year":"2000","journal-title":"JAMA"},{"issue":"21","key":"jrv200007r33","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"The effect of carvedilol on morbidity and mortality in patients with chronic heart failure.","volume":"334","author":"Packer","year":"1996","journal-title":"N Engl J Med"},{"issue":"10","key":"jrv200007r34","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial.","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N Engl J Med"},{"issue":"8875","key":"jrv200007r35","first-page":"821","article-title":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure.","volume":"342","author":"The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators","year":"1993","journal-title":"Lancet"},{"issue":"5","key":"jrv200007r36","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.","volume":"325","author":"Yusuf","year":"1991","journal-title":"N Engl J Med"},{"issue":"9386","key":"jrv200007r37","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"issue":"9335","key":"jrv200007r38","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","article-title":"Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial: Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan.","volume":"360","author":"Dickstein","year":"2002","journal-title":"Lancet"},{"issue":"23","key":"jrv200007r39","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"issue":"11","key":"jrv200007r40","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure.","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"issue":"19","key":"jrv200007r41","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1161\/CIRCULATIONAHA.118.039331","article-title":"Clinical outcomes in patients with acute decompensated heart failure randomly assigned to sacubitril\/valsartan or enalapril in the PIONEER-HF Trial.","volume":"139","author":"Morrow","year":"2019","journal-title":"Circulation"},{"issue":"10","key":"jrv200007r42","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure.","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"issue":"20","key":"jrv200007r43","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1056\/NEJMoa042934","article-title":"Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.","volume":"351","author":"Taylor","year":"2004","journal-title":"N Engl J Med"},{"issue":"9744","key":"jrv200007r44","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"issue":"23","key":"jrv200007r45","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).","volume":"316","author":"CONSENSUS Trial Study Group","year":"1987","journal-title":"N Engl J Med"},{"issue":"10","key":"jrv200007r46","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.","volume":"327","author":"Yusuf","year":"1992","journal-title":"N Engl J Med"},{"issue":"18","key":"jrv200007r47","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1001\/jama.1995.03520420066040","article-title":"Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure.","volume":"273","author":"Garg","year":"1995","journal-title":"JAMA"},{"issue":"9386","key":"jrv200007r48","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"issue":"6","key":"jrv200007r49","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure.","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"jrv200007r50","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1002\/ejhf.v21.8","article-title":"Initiation of sacubitril\/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study.","volume":"21","author":"Wachter","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"jrv200007r51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jama.2019.12821","article-title":"Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction.","volume":"322","author":"Januzzi","year":"2019","journal-title":"JAMA"},{"issue":"17","key":"jrv200007r52","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction.","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"jrv200007r53","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure.","volume":"141","author":"Solomon","year":"2020","journal-title":"Circulation"},{"issue":"22","key":"jrv200007r54","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in severe chronic heart failure.","volume":"344","author":"Packer","year":"2001","journal-title":"N Engl J Med"},{"issue":"9961","key":"jrv200007r55","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1016\/S0140-6736(14)61373-8","article-title":"Efficacy of \u00df blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis.","volume":"384","author":"Kotecha","year":"2014","journal-title":"Lancet"},{"issue":"17","key":"jrv200007r56","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1016\/j.jacc.2010.01.023","article-title":"Maintenance of sinus rhythm and survival in patients with heart failure and atrial fibrillation.","volume":"55","author":"Talajic","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"jrv200007r57","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12916-017-0781-0","article-title":"Respiratory effect of beta-blockers in people with asthma and cardiovascular disease: population-based nested case control study.","volume":"15","author":"Morales","year":"2017","journal-title":"BMC Med"},{"issue":"1","key":"jrv200007r58","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms.","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"issue":"14","key":"jrv200007r59","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"jrv200007r60","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2165\/00002018-200831020-00001","article-title":"I f inhibition with ivabradine : electrophysiological effects and safety.","volume":"31","author":"Savelieva","year":"2008","journal-title":"Drug Saf"},{"issue":"24","key":"jrv200007r61","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1016\/j.jacc.2017.04.001","article-title":"Heart rate and rhythm and the benefit of beta-blockers in patients with heart failure.","volume":"69","author":"Kotecha","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"jrv200007r62","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency.","volume":"361","author":"Anker","year":"2009","journal-title":"N Engl J Med"},{"issue":"11","key":"jrv200007r63","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","article-title":"Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency.","volume":"36","author":"Ponikowski","year":"2015","journal-title":"Eur Heart J"},{"issue":"19","key":"jrv200007r64","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1001\/jama.2017.5427","article-title":"Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial.","volume":"317","author":"Lewis","year":"2017","journal-title":"JAMA"},{"issue":"3","key":"jrv200007r65","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jchf.2019.09.011","article-title":"Mineralocorticoid receptor antagonists, blood pressure, and outcomes in heart failure with reduced ejection fraction.","volume":"8","author":"Serenelli","year":"2020","journal-title":"JACC Heart Fail"},{"issue":"4","key":"jrv200007r66","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jacc.2018.05.023","article-title":"Are guidelines merely suggestions?","volume":"72","author":"Jefferies","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"jrv200007r67","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jama.2020.1906","article-title":"Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes.","volume":"323","author":"Petrie","year":"2020","journal-title":"JAMA"},{"issue":"9","key":"jrv200007r68","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1001\/jamacardio.2017.2275","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action.","volume":"2","author":"Packer","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"10","key":"jrv200007r69","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review.","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"issue":"17","key":"jrv200007r70","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.117.030012","article-title":"Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials.","volume":"136","author":"Lytvyn","year":"2017","journal-title":"Circulation"},{"key":"jrv200007r71","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.120.047086","article-title":"Comparing the benefit of novel therapies across clinical trials: insights from the VICTORIA trial.","author":"Butler","year":"2020","journal-title":"Circulation"},{"issue":"15","key":"jrv200007r72","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1056\/NEJMoa050496","article-title":"The effect of cardiac resynchronization on morbidity and mortality in heart failure.","volume":"352","author":"Cleland","year":"2005","journal-title":"N Engl J Med"},{"issue":"14","key":"jrv200007r73","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa0906431","article-title":"Cardiac-resynchronization therapy for the prevention of heart-failure events.","volume":"361","author":"Moss","year":"2009","journal-title":"N Engl J Med"},{"issue":"12","key":"jrv200007r74","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa013474","article-title":"Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.","volume":"346","author":"Moss","year":"2002","journal-title":"N Engl J Med"},{"issue":"3","key":"jrv200007r75","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1056\/NEJMoa043399","article-title":"Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.","volume":"352","author":"Bardy","year":"2005","journal-title":"N Engl J Med"},{"issue":"21","key":"jrv200007r76","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1056\/NEJMoa033088","article-title":"Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy.","volume":"350","author":"Kadish","year":"2004","journal-title":"N Engl J Med"},{"issue":"24","key":"jrv200007r77","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1806640","article-title":"Transcatheter Mitral-valve repair in patients with heart failure.","volume":"379","author":"Stone","year":"2018","journal-title":"N Engl J Med"},{"issue":"24","key":"jrv200007r78","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1056\/NEJMoa1805374","article-title":"Percutaneous repair or medical treatment for secondary mitral regurgitation.","volume":"379","author":"Obadia","year":"2018","journal-title":"N Engl J Med"},{"issue":"15","key":"jrv200007r79","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/j.jacc.2017.08.010","article-title":"Pulmonary artery pressure-guided management of patients with heart failure and reduced ejection fraction.","volume":"70","author":"Givertz","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"jrv200007r80","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1161\/CIRCULATIONAHA.110.960898","article-title":"Effectiveness of cardiac resynchronization therapy by qrs morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT).","volume":"123","author":"Zareba","year":"2011","journal-title":"Circulation"},{"issue":"15","key":"jrv200007r81","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1056\/NEJMoa1306687","article-title":"Cardiac-resynchronization therapy in heart failure with a narrow QRS complex.","volume":"369","author":"Ruschitzka","year":"2013","journal-title":"N Engl J Med"},{"issue":"13","key":"jrv200007r82","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMoa1608029","article-title":"Defibrillator implantation in patients with nonischemic systolic heart failure.","volume":"375","author":"K\u00f8ber","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"jrv200007r83","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1001\/jamacardio.2019.5971","article-title":"New evidence supporting a novel conceptual framework for distinguishing proportionate and disproportionate functional mitral regurgitation.","volume":"5","author":"Packer","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"4","key":"jrv200007r84","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1001\/jamacardio.2019.5980","article-title":"An appraisal of the association of clinical outcomes with the severity of regurgitant volume relative to end-diastolic volume in patients with secondary mitral regurgitation.","volume":"5","author":"Gaasch","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"7","key":"jrv200007r85","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/S0735-1097(03)00947-1","article-title":"Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure.","volume":"42","author":"Braunstein","year":"2003","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"jrv200007r86","doi-asserted-by":"publisher","first-page":"3200","DOI":"10.1016\/j.jacc.2018.09.020","article-title":"2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.","volume":"72","author":"Das","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"jrv200007r87","doi-asserted-by":"publisher","first-page":"e294","DOI":"10.1161\/CIR.0000000000000691","article-title":"Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC\/AHA\/HFSA heart failure guideline update.","volume":"140","author":"Dunlay","year":"2019","journal-title":"Circulation"},{"issue":"2","key":"jrv200007r88","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"issue":"14","key":"jrv200007r89","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"issue":"5","key":"jrv200007r90","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial.","volume":"316","author":"Margulies","year":"2016","journal-title":"JAMA"},{"issue":"7","key":"jrv200007r91","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/eurjhf\/hfp085","article-title":"A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure.","volume":"11","author":"Mamas","year":"2009","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"jrv200007r92","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1707855","article-title":"Catheter ablation for atrial fibrillation with heart failure.","volume":"378","author":"Marrouche","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"jrv200007r93","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1002\/ejhf.2017.19.issue-12","article-title":"Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction.","volume":"19","author":"L\u00f6fman","year":"2017","journal-title":"Eur J Heart Fail"},{"issue":"16","key":"jrv200007r94","doi-asserted-by":"publisher","first-page":"e840","DOI":"10.1161\/CIR.0000000000000664","article-title":"Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association.","volume":"139","author":"Rangaswami","year":"2019","journal-title":"Circulation"},{"issue":"10","key":"jrv200007r95","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.jacc.2019.12.059","article-title":"Diuretic therapy for patients with heart failure: JACC state-of-the-art review.","volume":"75","author":"Felker","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"jrv200007r96","doi-asserted-by":"publisher","first-page":"4939","DOI":"10.1038\/s41598-017-04949-2","article-title":"Key Role for the organic anion transporters, OAT1 and OAT3, in the in vivo handling of uremic toxins and solutes.","volume":"7","author":"Wu","year":"2017","journal-title":"Sci Rep"},{"issue":"2","key":"jrv200007r97","doi-asserted-by":"publisher","first-page":"20A","DOI":"10.1016\/0002-9149(86)91002-7","article-title":"Disposition and response to bumetanide and furosemide.","volume":"57","author":"Brater","year":"1986","journal-title":"Am J Cardiol"},{"issue":"2","key":"jrv200007r98","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/0735-1097(96)00161-1","article-title":"Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion.","volume":"28","author":"Dormans","year":"1996","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"jrv200007r99","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.jchf.2018.01.024","article-title":"Percutaneous revascularization for ischemic ventricular dysfunction: rationale and design of the REVIVED-BCIS2 trial: percutaneous coronary intervention for ischemic cardiomyopathy.","volume":"6","author":"Perera","year":"2018","journal-title":"JACC Heart Fail"},{"issue":"17","key":"jrv200007r100","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1056\/NEJMoa1100356","article-title":"Coronary-artery bypass surgery in patients with left ventricular dysfunction.","volume":"364","author":"Velazquez","year":"2011","journal-title":"N Engl J Med"},{"issue":"16","key":"jrv200007r101","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1056\/NEJMoa1602001","article-title":"Coronary-artery bypass surgery in patients with ischemic cardiomyopathy.","volume":"374","author":"Velazquez","year":"2016","journal-title":"N Engl J Med"},{"issue":"7B","key":"jrv200007r102","doi-asserted-by":"publisher","first-page":"3i","DOI":"10.1016\/j.amjcard.2005.07.028","article-title":"Heart failure in African Americans.","volume":"96","author":"Yancy","year":"2005","journal-title":"Am J Cardiol"},{"key":"jrv200007r103","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ijcard.2018.03.121","article-title":"Angioedema in heart failure patients treated with sacubitril\/valsartan (LCZ696) or enalapril in the PARADIGM-HF study.","volume":"264","author":"Shi","year":"2018","journal-title":"Int J Cardiol"},{"issue":"8","key":"jrv200007r104","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.cardfail.2015.05.013","article-title":"Heart failure in non-caucasians, women, and older adults: a white paper on special populations from the Heart Failure Society of America Guideline Committee.","volume":"21","author":"Colvin","year":"2015","journal-title":"J Card Fail"},{"issue":"3","key":"jrv200007r105","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.ejheart.2004.10.004","article-title":"Randomised controlled trial of cardiac rehabilitation in elderly patients with heart failure.","volume":"7","author":"Austin","year":"2005","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"jrv200007r106","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1161\/01.CIR.0000055013.92097.40","article-title":"Exercise and heart failure: A statement from the American Heart Association Committee on exercise, rehabilitation, and prevention.","volume":"107","author":"Pi\u00f1a","year":"2003","journal-title":"Circulation"},{"issue":"14","key":"jrv200007r107","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1001\/jama.2009.454","article-title":"Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial.","volume":"301","author":"O\u2019Connor","year":"2009","journal-title":"JAMA"},{"issue":"6","key":"jrv200007r108","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1161\/CIRCULATIONAHA.104.492033","article-title":"Changing incidence and survival for heart failure in a well-defined older population, 1970-1974 and 1990-1994.","volume":"113","author":"Barker","year":"2006","journal-title":"Circulation"},{"issue":"8","key":"jrv200007r109","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.jchf.2018.03.006","article-title":"Temporal trends in the incidence of and mortality associated with heart  failure with preserved and reduced ejection fraction.","volume":"6","author":"Tsao","year":"2018","journal-title":"JACC Heart Fail"},{"issue":"5","key":"jrv200007r110","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jchf.2014.04.006","article-title":"Factors influencing the predictive power of models for predicting mortality and\/or heart failure hospitalization in patients with heart failure.","volume":"2","author":"Ouwerkerk","year":"2014","journal-title":"JACC Heart Fail"},{"issue":"5","key":"jrv200007r111","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jchf.2014.04.008","article-title":"Risk prediction in patients with heart failure: a systematic review and analysis.","volume":"2","author":"Rahimi","year":"2014","journal-title":"JACC Heart Fail"},{"issue":"4","key":"jrv200007r112","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jamacardio.2019.5850","article-title":"Prognostic Models derived in PARADIGM-HF and validated in ATMOSPHERE and the Swedish Heart Failure Registry to predict mortality and morbidity in chronic heart failure.","volume":"5","author":"Simpson","year":"2020","journal-title":"JAMA Cardiol"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2768982\/jama_murphy_2020_rv_200007_1605896147.19162.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T22:45:27Z","timestamp":1606257927000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2768982"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2020,8,4]]},"references-count":112,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,8,4]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2020.10262","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8,4]]}}}